

VCN Biosciences has secured intellectual property rights in Spain for the hyaluronidase technology included in its lead candidate VCN-01.

The Spanish Office for Patents and Trademarks (OEMPS) granted a patent (ES23852251 B1) entitled "Adenovirus oncolíticos para el tratamiento del cancer". The claims cover oncolytic adenoviruses expressing hyaluronidase enzyme to enhance its antitumoral efficacy.